Halifax Genetic Testing Program Saves Lives by Identifying Hereditary Cancer Risks
A pioneering genetic testing program at IWK Health in Halifax is improving cancer care across Canada by identifying hereditary predispositions to myeloid malignancies and ruling out unsuitable stem-cell donors.
A specialized genetic testing program developed in the Maritimes is transforming cancer care across Canada. Based at the IWK Maritime Centre for Precision Medicine in Halifax, the initiative focuses on hereditary myeloid malignancies and has been credited with saving lives by preventing unsafe bone marrow transplants.
The clinical program was developed by hematologist Dr. Amy Trottier. It utilizes hereditary genetic testing to identify patient predispositions to leukemia and other blood cancers. This approach allows medical teams to rule out family members who might otherwise be considered suitable stem-cell donors but carry similar genetic risks.
Ryan White’s experience illustrates the critical impact of this technology. Diagnosed with acute myeloid leukemia in 2020 after experiencing shortness of breath and low energy, White underwent chemotherapy in May 2020. Although he entered remission, the cancer returned later that year.
Hereditary genetic testing revealed that White had a predisposition for the cancer, which explained why it recurred despite initial treatment success. The results allowed doctors to rule out his sibling, who had initially been identified as a perfect match for a bone marrow transplant. Using an alternative donor, White’s treatment plan was customized based on his unique genetic factors.
April 8th marked the fifth-year anniversary of White being in remission. He credits the testing with saving his life by ensuring he received a safe and effective transplant.
IWK Health is one of only two centres in Canada offering this specialized genetic testing. Lee Anne Boutilier, the director of Precision Medicine at IWK Health, oversees the program, which serves as a referral centre for the rest of the country. By identifying these hereditary risks, the program is helping to improve cancer care standards nationwide.